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AbstrAct
The Food and Drug Administration recently 
approved the combination of phentermine and 
extended-release topiramate (PHN/TPM) for 
weight loss. This is one of only two weight-loss 
agents to arrive on the US market in the last 
decade. This product combines the anorexigenic 
agent, phentermine, which is approved for the 
short-term treatment of weight loss, with a 
carbonic anhydrase inhibitor, topiramate, which 
is approved for non-weight loss indications, 
including seizure disorders and migraine 
headache. Although the combination is believed 
to be synergistic, no clinical trial data currently 
address this. The PHN/TPM combination is a 
once-daily formulation. Mean weight loss among 
participants who completed 1 year of PHN/TPM 
treatment in research trials, in combination 
with lifestyle modification, has ranged from 
approximately 7% (lower doses) to over 14% 
(higher doses), relative to approximately 2% with 
placebo. In addition to weight loss, PHN/TPM 
resulted in improved comorbidities and quality 
of life, although it has not been shown to 
improve mental/psychosocial issues. Among the 
common adverse events observed in clinical trials 
are paresthesia, dry mouth, constipation, and 
headache. Other noteworthy adverse events that 
occurred more commonly with PHN/TPM versus 
placebo included dysgeusia, insomnia, irritability, 
and alopecia. Laboratory abnormalities in serum 
bicarbonate and potassium were also observed 
in a subset of patients. Due to the teratogenic 
potential of topiramate, women of child-
bearing potential are required to have a negative 
pregnancy test at baseline and are instructed to 
take monthly pregnancy tests. As part of a risk-
management approach, only pharmacies certified 
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by the manufacturer will be allowed to dispense 
PHN/TPM and will be required to provide 
information on birth defects. Like phentermine, 
the combination drug will be designated as a 
schedule IV medication. In comparison with 
other agents currently on the market, the 
combination of PHN/TPM appears to provide 
significant advantages for weight loss, while 
improving comorbid conditions and quality of 
life. Monitoring for laboratory abnormalities, 
adverse events, and changes in psychiatric status 
should occur during therapy. 
Keywords: Combination; Obesity; Phentermine; 
Phentermine/topiramate; Topiramate; Weight 
loss
INtrODUctION
Obesity leads to premature death [1] and impairs 
quality of life [2–4]. A representative sample of 
US adults in 2009–2010 indicated that 35.5% 
of men and 35.8% of women are obese [5]. 
Healthcare expenditures attributable to obesity 
were projected to reach $147 billion in 2008 [6]. 
In 2006, per capita medical spending was $1,429 
higher for obese versus nonobese individuals [6]. 
Obesity is associated with several of the most 
common causes of mortality in the US: heart 
disease, stroke, certain cancers, diabetes, and 
renal disease [7]. One in every eight deaths is 
attributable to an illness directly related to obesity 
[8]. Despite these individual and societal burdens 
of obesity, treatment options remain limited. 
A minority of patients is extremely successful 
in attaining and maintaining significant weight 
loss through lifestyle modification alone [9]. For 
the majority, however, lifestyle modification 
in the absence of a behavioral weight-loss 
program, pharmacotherapy regimen, or weight-
loss surgery is inadequate. Pharmacotherapy 
is a much needed intermediate intervention 
for those who are unsuccessful with lifestyle 
intervention alone and for whom weight-loss 
surgery is not indicated or desired. Currently, 
the pharmacotherapeutic options for obesity 
management are extremely limited. Although 
several drugs are in the obesity pipeline, the 
process for getting such drugs to market has 
recently proven difficult. 
MAtErIALs AND MEtHODs
Studies were found using PubMed. No limits 
on dates were set. Major keywords included 
phentermine and topiramate, phentermine, 
topiramate, pharmacotherapy for weight loss, 
lorcaserin, orlistat, and others.
INDIcAtIONs AND 
EFFIcAcY bENcHMArKs FOr 
PHArMAcOtHErAPY 
Pharmacotherapy for obesity is indicated for 
patients with a body mass index (BMI) ≥30 kg/m2
or 27–29.9 kg/m2 with a comorbid condition 
that increases cardiometabolic risk [10]. 
Pharmacotherapy is indicated in conjunction 
with supportive lifestyle modification 
counseling [11], and should be used with a 
reduced calorie diet and exercise regimen. 
Current indications for bariatric surgery include 
a BMI of ≥40 kg/m2 or ≥35 kg/m2 with significant 
obesity-related disorders [12]. Therefore, a 
substantial percentage of the population who 
are overweight/obese but do not meet criteria 
for surgery may benefit from a pharmacological 
intervention. 
According to the US Food and Drug 
Administration (FDA), a weight-loss medication 
is deemed effective if it demonstrates one of 
the following after 1 year of treatment: (1) “The 
difference in mean weight loss between the 
active-product and placebo-treated groups is 
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at least 5% and the difference is statistically 
significant,” or (2) “The proportion of subjects 
who lose ≥5% of baseline body weight in 
the active-product group is at least 35%, is 
approximately double the proportion in the 
placebo-treated group, and the difference 
between groups is statistically significant.” 
In addition, the FDA expects improvements 
in blood pressure, lipids, glycemia, or other 
comorbidities that are commensurate with the 
degree of weight lost [13]. 
A PErILOUs PAst FOr WEIGHt-
LOss PHArMAcOtHErAPY
A historical look at the fate of some of the 
most commonly used prescription and herbal 
products for weight loss over the last three 
decades reveals multiple issues, which may 
have contributed to the FDA’s hesitancy in 
approving new medications. Dinitrophenol was 
withdrawn for risk of neuropathy and cataracts, 
aminorex was withdrawn due to pulmonary 
hypertension, and amphetamine use was 
discouraged due to risk of dependency and 
cardiac adverse events [14]. In 2004, the FDA 
mandated the removal of ephedrine-containing 
products due to cardiovascular concerns. 
Phenylpropanolamine, a sympathomimetic 
amine widely used as an appetite suppressant, 
was withdrawn in 2000 after being associated 
with intracranial hemorrhage [15]. 
Perhaps the most memorable pitfall in obesity 
pharmacotherapy involved fenfluramine-
phentermine (fen-phen) in 1997. Although 
this combination was efficacious and widely 
prescribed, fenfluramine was withdrawn 
following FDA concerns about cardiac valve 
damage [16, 17]. 
Sibutramine was withdrawn in 2010 after 
results of the Sibutramine Cardiovascular 
Outcomes Trial (SCOUT) became available [18]. 
The SCOUT trial was a large, placebo-controlled, 
multicenter trial sponsored by the drug’s 
manufacturer to determine whether the 
drug could reduce cardiovascular mortality 
in a high-risk sample. Contrary to the study 
hypothesis, patients receiving sibutramine had 
a significantly higher rate of cardiovascular 
events versus placebo with overall incidences of 
11.4% versus 10%, respectively. Although the 
sibutramine package labeling warned against 
treating patients at high cardiac risk, the FDA 
issued new warnings based upon these data, 
which ultimately led to the drug’s withdrawal. 
Although never available in the US market, 
cannabinoid 1 receptor (CB1) antagonists, such 
as rimonabant, were in late-stage development 
by several pharmaceutical companies before 
being aborted due to the increased risk of 
depression/suicide. Rimonabant was also 
removed from the European market.
Other weight-loss medications and 
drug combinations are in the development 
process, including bupropion/naltrexone, 
bupropion/zonisamide, and tesofensine. The 
FDA approved Qsymia™ (Vivus, Inc., Mountain 
View, California, USA), a combination of 




In addition to phentermine, which is approved 
for the short-term treatment (3 months) of 
obesity, two additional agents are approved for 
longer term use. Orlistat is a lipoprotein lipase 
inhibitor available in prescription (120 mg) 
and over-the-counter formulations (60 mg), 
which works by inhibiting the breakdown and 
absorption of dietary fat. The pharmacological 
activity of orlistat is localized to the 
gastrointestinal tract, with less than 2% of the 
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drug being absorbed into systemic circulation 
[19]. This results in a toxicity profile consisting 
of gastrointestinal adverse effects, but relatively 
few serious side effects. However, the efficacy 
of orlistat is modest. A meta-analysis of orlistat 
trials of at least 12 months in duration showed 
a mean weight loss of 2.89 kg (95% confidence 
intervals [CI]: 2.27–3.51 kg) [20].
Lorcaserin is a serotonin 2C agonist that was 
recently approved by the FDA for weight loss 
at a dose of 10 mg twice daily. In three large, 
controlled trials lasting 52–104 weeks, including 
approximately 8,000 patients, placebo-subtracted 
weight loss was 3.0–3.7%, when combined with 
reduced calorie diet and exercise [21]. The most 
common adverse effects of lorcaserin in patients 
without diabetes included headache, dizziness, 
fatigue, nausea, dry mouth, and constipation. In 
diabetic patients, the most common side effects 
included hypoglycemia, headache, back pain, 
cough, and fatigue [21]. 
PHENtErMINE/EXtENDED-rELEAsE 
tOPIrAMAtE 
In July 2010, an FDA advisory committee 
rejected PHN/TPM, with a vote of 10 to 6, 
due to concerns about increased heart rate, 
teratogenicity, and suicidality. In October 2010, 
the FDA requested additional data from Vivus, 
its manufacturer, to address these concerns. 
In February 2012, an FDA Scientific Advisory 
Committee recommended approval of PHN/TPM 
with some changes from the original submission. 
In July of 2012, PHN/TPM (formerly Qnexa® 
[Vivus, Inc.]) was approved as a schedule IV drug 
under the brand name, Qsymia™. 
FOrMULAtION AND DOsAGEs
PHN/TPM is a combination of an immediate-
release formulation of the anorexigenic 
agent, phentermine, and an extended-release 
formulation of the anticonvulsant medication, 
topiramate. Phentermine, with a history of 
use spanning 52 years, is currently the most 
widely prescribed drug for weight loss in the 
US with over 6.5 million prescriptions written 
in 2011 [22]. Topiramate has a 15-year history 
of use. The drug combination is formulated to 
produce peak exposure to phentermine in the 
morning and peak concentrations of topiramate 
in the evening [22]. 
The drug was approved in four dosage 
strengths of PHN/TPM: 3.75/23 mg, 7.5/46 mg, 
11.25/69 mg, and 15/92 mg. The scientific 
rationale for the specific doses included in the 
combination is not clear, for example, 92 mg 
topiramate instead of the commercially available 
100 mg dosage form of topiramate. The doses of 
topiramate used for weight loss are somewhat 
lower than for the other indications of the 
drug. The recommended migraine headache 
prophylaxis dose is 100 mg/day given in two 
divided doses [23]. The dose for partial-onset 
seizure and primary generalized tonic-clonic 
seizure is up to a maximum of 400 mg/day 
given in two divided doses, and similar doses 
are used for adjunctive therapy in these 
seizure disorders [24]. Topiramate doses up to 
1,600 mg/day have been studied in epilepsy [23]. 
For weight loss, the recommended dosing 
is 3.75/23 mg once daily (in the morning) for 
14 days with an increase to 7.5/46 mg thereafter 
[25]. If at least 3% of baseline body weight 
has not been lost after 12 weeks, the dose 
may be escalated or discontinued. If the dose 
is escalated, it should be done by prescribing 
the 11.25/69 mg dose for 14 days followed by 
increasing to the 15/92 mg dose. If after an 
additional 12 weeks on PHN/TPM 15/92 mg 
the patient has not experienced 5% weight loss, 
the drug should be discontinued [25]. Doses of 
3.75/23 mg and 11.25/69 mg should be used for 
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titration purposes [25]. When discontinued, the 
drug should be reduced gradually by taking a 
dose every other day for at least a week before 
stopping treatment to prevent the precipitation 
of seizures [25]. In patients with moderate 
(creatine clearance ≥30 to <50 mL/min) and 
severe (<30 mL/min) renal dysfunction, the 
maximum dose should not exceed 7.5/46 mg. 
MEcHANIsM OF ActION AND 
EFFIcAcY OF INDIVIDUAL AGENts
Topiramate
It has been suggested that topiramate and 
phentermine may have synergistic effects 
toward weight loss [26], although this theory 
has not been tested in clinical trials. Until 
the combination of PHN/TPM is compared 
against each of the agents individually, claims 
of synergy cannot be addressed. Topiramate is 
currently FDA-approved for the treatment of 
seizure disorders and prophylaxis of migraine 
headaches [23]. The mechanism of action that 
contributes to weight loss is currently unclear. 
The pharmacology of topiramate is complex. It 
is known to block neuronal voltage-dependent 
sodium channels, antagonize 2-amino-3-
(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid/
kainite glutamate receptors, enhance gamma-
aminobutyric acid activity, and weakly inhibit 
carbonic anhydrase [23]. 
Topiramate has been associated with 
weight loss in many treatment trials, including 
epilepsy [24], migraine headache [27, 28], bulimia 
nervosa [29, 30], binge-eating disorder [31, 32], 
antipsychotic-associated weight gain [33, 34], 
and obesity [35]. A recent meta-analysis [35] 
evaluated weight loss associated with topiramate 
across 10 randomized, controlled trials (RCTs) in 
overweight or obese patients, with or without 
comorbid conditions. Overall, patients lost an 
average of 5.34 kg (95% CI –6.12 to –4.56 kg) 
beyond the loss observed with placebo [35]. 
This meta-analysis also showed that trials with 
longer treatment durations (>28 weeks duration) 
demonstrated greater weight loss (6.58 kg; [95% 
CI –7.48 to –5.68 kg]) and that doses over 96 mg/
day were associated with higher discontinuation 
rates in trials. 
A recent 3-month study of 40 patients treated 
with topiramate 100 mg/day for migraine 
prophylaxis found no change in resting metabolic 
rate [36]. There were, however, statistically 
significant reductions in mean BMI, body fat 
ratio, and abdominal skin-fold measurements. 
The findings of this study led the authors to 
conclude that the anorexigenic activity of 
topiramate may occur through hypothalamic 
activity. It has been suggested that topiramate 
may also lead to weight loss through increased 
satiety due to decreased gastrointestinal motility, 
increased taste aversion, increased energy 
expenditure, and decreased caloric intake [22]. 
The propensity of topiramate to contribute to 
neuropsychiatric and cognitive events at higher 
dosages has hindered its development as a 
monotherapy for weight loss [37]. 
PHENtErMINE
Phentermine was approved by the FDA in 1959. 
Appetite reduction associated with phentermine 
is thought to be centrally mediated, including 
hypothalamic stimulation that results in 
norepinephrine release [23]. Phentermine 
is indicated for short-term use for weight 
reduction, in combination with a reduced 
calorie diet and exercise [23]. The utility of 
phentermine when used short-term according 
to its labeling is questionable. 
Off-label use of phentermine has been 
examined in clinical trials of longer duration. 
A meta-analysis [20] evaluated the results 
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of six placebo-controlled RCTs. These trials 
ranged from 2–24 weeks and involved dosages 
of 15–30 mg/day. Lifestyle intervention was 
included in over 80% of patients. The average 
weight loss in these trials was 3.6 kg (95% CI 
0.6–6.0 kg) above placebo. 
Phentermine is generally well-tolerated. 
Common side effects are characteristic of 
sympathomimetic amines, including dry mouth, 
headache, insomnia, nervousness, irritability, and 
constipation. More serious side effects include 
palpitations, tachycardia, and hypertension 
[38]. Phentermine should be avoided in patients 
with hyperthyroidism, glaucoma, agitated 
states, advanced arteriosclerosis, symptomatic 
cardiovascular disease, moderate-severe 
hypertension, a history of substance abuse, or 
those who would have a drug interaction (e.g., 
monoamine oxidase inhibitors). 
cLINIcAL trIALs INVOLVING 
PHN/tPM
Three large RCTs address the efficacy of 
PHN/TPM for weight loss. A fourth trial has been 
completed but not yet published (EQUATE). 
These trials provide efficacy and tolerability 
information regarding the effect of this drug 
combination on comorbid conditions. All 
trials were funded by Vivus, the manufacturer 
of the PHN/TPM combination. The published 
trials include: CONQUER [37], EQUIP [39], and 
SEQUEL [40]. The results of each of these trials 
will be discussed in detail and a summary of 
each is presented in Table 1 [37, 39, 40]. 
The EQUIP study [39] was a 56-week, 
three-arm, double-blind, parallel-group study 
conducted at 91 centers across the US. The study 
included a blinded 4-week titration period and 
subsequent 52-week treatment period. Patients 
18–70 years of age were included who had 
a BMI of ≥35 kg/m2. Patients were relatively 
free of comorbid conditions. Participants 
were randomized in a 2:1:2 ratio to placebo 
(n = 514), PHN/TPM 3.75/23 mg (n = 241), and 
PHN/TPM 15/92 mg (n = 512). Participants 
were provided with “standardized lifestyle 
counseling” based upon the Lifestyle, Exercise, 
Attitudes, Relationships, and Nutrition (LEARN) 
manual [41] and were instructed to follow a 
500 kcal dietary reduction along with increased 
water intake with increased physical activity. 
Participants were mostly women (83%) and the 
mean total BMI was 42 kg/m2. 
The CONQUER study [37] was a 56-week, 
randomized, double-blind RCT conducted 
at 93 centers across the US. Participants 
18–70 years of age were enrolled with a BMI 
≥27–≤45 kg/m2, with two or more comorbid 
conditions (hypertension, hyperlipidemia, 
diabetes, impaired glucose tolerance, or high 
waist circumference). The majority of patients 
in this trial were women (70%), and the mean 
BMI was 36.6 kg/m2. Comorbidity rates were 
hypertension (52%), hypertriglyceridemia 
(36%), impaired glucose tolerance or impaired 
fasting glucose (68%), and type 2 diabetes (16%). 
Patients were randomized in a 2:1:2 ratio to 
either daily placebo, PHN/TPM 7.5/46 mg, or 
PHN/TPM 15/92 mg. As with EQUIP, participants 
received lifestyle counseling, and dietary and 
fitness instructions. 
The SEQUEL study [40] assessed the efficacy 
and safety of PHN/TPM for longer-term use 
in overweight/obese individuals with existing 
cardiometabolic disease. This was a 52-week, 
placebo-controlled, double-blind, extension 
study following CONQUER. Participants who 
completed and complied with the CONQUER 
trial were eligible for SEQUEL. Patients continued 
the product to which they were originally 
randomized, in conjunction with lifestyle 
modification. Interestingly, more participants met 
criteria for type 2 diabetes mellitus at baseline in 
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Table 1  Overview of major PHN/TPM studies
Study name, Study duration, Participants: Efficacy:  Attrition and reasons 
primary author,  study design, N, characteristics % weight loss 
year, study sponsor intervention(s) 
EQUIP [39] 56 weeks plc: n = 514 ITT analysis: Completion rates:
  3.75/23: n = 241 plc: 1.6% total: 53.7%
Allison et al., 2011 DB, RCT 15/92: n = 512 3.75/23: 5.1% plc: 46.9%  
   15/92: 10.9% 3.75/23: 57.3%
Vivus, Inc. Energy deficit, LEARN M & F  15/92: 58.8%
 manual + one of Age 18–70 years Completer analysis:  
 three groups BMI ≥35 kg/m2 plc: 2.1% Most common reasons:
   3.75/23: 6.7% - lost to follow-up
   15/92: 14.4% - withdrawal of consent
    - adverse events
CONQUER [37] 56 weeks plc: n = 994 ITT analysis: Completion rates:
  7.5/46: n = 498 plc: 1.2% total: 69.3%
Gadde et al., 2011 DB, RCT 15/92: n = 995 7.5/46: 7.8% plc: 62%
   15/92: 9.8% 7.5/46: 75.1%
    15/92: 73.7%
Vivus, Inc. Energy deficit, LEARN BMI ≥27 and Completer analysis:  
 manual + one of ≤45 kg/m2 + two plc: 1.6% 
 three groups or more 7.5/46: 9.6% 
  comorbidities 15/92: 12.4%
SEQUEL [40] 52-week extension n (% of CONQUER ITT-LOCF: Completion rates
 after 56-week patients) plc: 1.8% (weeks 56–108):
   7.5/46: 9.3% plc: 86.3%
Garvey et al., 2012 CONQUER study plc: 227 (69.4%) 15/92: 10.5% 7.5/46: 82.5%
  7.5/46: 153 (79.4%)  15/92: 83.1%
  15/92: 295 (85.5%)  
Vivus, Inc. DB, PC BMI ≥22 kg/m2 Completer analysis: Most common reasons
 Lifestyle modification +  plc: 2.2% - lost to follow-up
 continuation in one of  7.5/46: 9.3% - withdrew consent
 three groups  15/92: 10.7% - adverse event
3.75/23 phentermine 3.75 mg + topiramate 23 mg extended-release capsules, 15/92 phentermine 15 mg + topiramate 92 mg 
extended-release capsules, 7.5/46 phentermine 7.5 mg + topiramate 46 mg extended-release capsule, BMI body mass index, 
DB double-blind, F female, ITT intention to treat, LEARN Lifestyle, Exercise, Attitudes, Relationships, and Nutrition, 
LOCF last observation carried forward, M male, PC placebo-controlled, PHN/TPM phentermine and extended-release 
topiramate, plc placebo, RCT randomized, controlled trial
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the SEQUEL extension study compared with the 
CONQUER cohort (21.5% vs. 15.8%). Percentage 
rates of participation were as follows: 15/92 mg 
(85.5%), 7.5/46 mg (79.4%), placebo (69.4%). 
EFFIcAcY FOr WEIGHt LOss
In the EQUIP trial, weight loss was highest for 
patients in the 15/92 mg PHN/TPM group, and 
both drug groups lost significantly more weight 
than placebo in each analysis. Study completers 
lost 14.4% of baseline weight on PHN/TPM 
15/92 mg, 6.7% on PHN/TPM 3.75/23 mg, and 
2.1% on placebo. Higher percentages of patients 
lost at least 5%, 10%, and 15% of baseline weight 
on active medication versus placebo. Weight loss 
≥10% was achieved by 67.7% of participants 
with PHN/TPM 15/92 mg, 27.7% with PHN/TPM 
3.75/23 mg, and 13.0% with placebo. 
The CONQUER trial showed significantly 
greater weight reductions for both drug groups 
versus placebo. The completer analysis showed 
reductions of –9.9 kg (least squares mean –9.6%), 
–12.9 kg (–12.4%), and –1.8 kg (–1.6%) with 
PHN/TPM 7.5/46 mg, 15/92 mg, and placebo, 
respectively. Significantly higher percentages of 
participants lost ≥10% of baseline weight in the 
PHN/TPM groups. This threshold was reached by 
37% in the PHN/TPM 7.5/46 mg group, 48% in 
the PHN/TPM 15/92 mg group, and 7% in the 
placebo group in ITT analyses. 
Weight-loss efficacy in SEQUEL was greater 
in both medication groups versus placebo. Least 
squares mean percentage change in weight from 
baseline to week 108 in the intent-to-treat (ITT) 
Last Observation Carried Forward (LOCF) analysis 
was significantly greater in the PHN/TPM groups 
versus placebo: –9.3% (PHN/TPM 7.5/46 mg), 
–10.5% (PHN/TPM 15/92 mg), and –1.8% (placebo). 
A completer analysis revealed similar results. 
Significantly more patients in both drug 
groups achieved losses of 5%, 10%, and 15% 
versus placebo. More patients in the 15/92 mg 
dose group lost 20% or more of baseline body 
weight versus those on placebo. In SEQUEL, 
the PHN/TPM 15/92 mg dose was found to be 
superior to the 7.5/46 mg dose and placebo for 
weight loss in participants with the highest BMIs 
(baseline BMI 40 and 45 kg/m2). 
Weight loss observed in trials of PHN/TPM 
appears to be greater than weight loss reported 
in lorcaserin trials and in some of the trials 
of bupropion/naltrexone. In three large 
(approximately 8,000 patients) lorcaserin RCTs 
of 52–104 weeks duration, weight loss was 
3.0–3.7% versus placebo when combined with 
reduced calorie diet and exercise [21]. Data 
from the first year of treatment in the large 
Behavioral Modification and Lorcaserin Second 
Study for Obesity Management (BLOSSOM) 
and Behavioral Modification and Lorcaserin for 
Overweight and Obesity Management (BLOOM) 
trials of lorcaserin showed a 5.8% weight 
loss [42]. In four large 56-week bupropion/
naltrexone trials consisting of approximately 
4,500 patients, weight loss ranged from 
approximately 5.0–9.3% [43]. 
EFFIcAcY FOr WEIGHt-rELAtED 
cOMOrbID cONDItIONs
In EQUIP, comorbidities improved significantly 
with 15/92 mg PHN/TPM versus placebo for 
waist circumference, systolic blood pressure 
(SBP), diastolic blood pressure (DBP), glucose, 
triglycerides, total cholesterol/high-density 
lipoprotein (HDL) ratio, total cholesterol, low-
density lipoprotein (LDL) cholesterol, and HDL 
cholesterol. Improvements in the PHN/TPM 
3.75/23 mg group did not always reach statistical 
significance when compared against placebo. 
Comorbidities in CONQUER were also 
generally improved in PHN/TPM versus placebo. 
Significant improvements were observed for 
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waist circumference, blood pressure, lipids, 
glycemia, C-reactive protein, and adiponectin. 
Among patients with hypertension, those 
on active PHN/TPM had a greater reduction 
in SBP versus placebo, and patients on 
PHN/TPM discontinued more antihypertensive 
medications versus placebo. A complication in 
interpretation of the comorbidity data from 
CONQUER is that patients’ comorbidities 
were managed according to the “standards of 
care” and concomitant medications could be 
adjusted accordingly. This makes it difficult to 
determine whether the PHN/TPM combination 
had an independent effect, or even a weight-loss 
mediated effect, on comorbid conditions beyond 
the improved monitoring and management 
that was provided as part of the study. The 
longer-term SEQUEL study found continued 
reduction in many comorbid conditions. 
Improvement in comorbidities can be reviewed 
in Table 2 [37, 39, 40]. 
ADVErsE EVENts
When PHN/TPM data were analyzed and 
presented to the FDA in aggregate, the most 
frequently reported treatment emergent adverse 
events included paresthesia (17%), dry mouth 
(16.6%), constipation (15.1%), upper respiratory 
tract infection (13.5%), nasopharyngitis (10%), 
and headache (9.8%) [22]. Additional dose-
related adverse effects that were more common 
in PHN/TPM versus placebo included dysgeusia, 
insomnia, irritability, and alopecia [22]. 
Additional information on study-specific adverse 
events may be found in Table 2.
LAbOrAtOrY AbNOrMALItIEs
It is thought that the inhibition in carbonic 
anhydrase that occurs with topiramate 
contributes to changes in bicarbonate, 
potassium, and risk of nephrolithiasis. 
When looking at laboratory results overall,
there were no differences between the medication 
and placebo groups regarding the incidence 
of serious laboratory-related adverse events or 
drug discontinuations due to laboratory adverse 
events [22]. There were, however, some notable 
laboratory findings reported in the major trials. 
All cases of hypokalemia associated with a 
potassium value <3 mmol/L plus a reduction of 
>0.5 mmol/L from baseline reportedly occurred 
in patients taking non-potassium-sparing 
diuretics [22]. More information on laboratory 
abnormalities that occurred during clinical trials 




In EQUIP, psychiatric side effects were assessed 
with the Patient Health Questionnaire-9 
(PHQ-9) [44] and the Columbia Suicide Severity 
Rating Scale (C-SSRS) [45]. Mean PHQ-9 
scores indicated improvements in depressive 
symptoms over time in all treatment groups, 
with no between group differences observed. No 
increases in suicidal ideation or behavior were 
identified on the C-SSRS for any participants. 
It should be noted that participants had 
minimal depressive symptoms at baseline 
(mean PHQ-9 = 2.8) due to exclusionary 
criteria (PHQ-9 >10). Data presented in study 
appendices reflect that there may be a small 
number of patients whose psychiatric function 
worsens while on the drug. Psychiatric and 
neurocognitive effects have not been specifically 
and thoroughly assessed in patients with clinical 
depression or other significant mental health 
disorders. Therefore, clinicians should monitor 
for any potential worsening of these conditions 
if PHN/TPM is started. 
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In CONQUER, no increase in suicidality was 
observed with drug versus placebo. Adverse 
event rates due to depression in the safety 
sample were similar in all three treatment 
groups (3–4%). Anxiety and irritability were 
significantly more common in the PHN/TPM 
15/92 mg group versus placebo (4% vs. 2% for 
anxiety; 3% vs. <1% for irritability). Generally, 
psychiatric adverse events occurred early in 
treatment (median 29 days in the PHN/TPM 
15/92 mg group) and lasted 29 days (median) 
in the PHN/TPM 15/92 mg group. Disturbance 
in attention was observed in 4% of those in the 
PHN/TPM 15/92 mg group, 2% in the PHN/TPM 
7.5/46 mg group, and <1% in the placebo group, 
differences that were significant for both drug 
groups versus placebo. These cognitive side 
effects emerged to a median of 23–25 days into 
treatment and lasted a median of 51 days in the 
PHN/TPM 7.5/46 mg group and 36 days in the 
PHN/TPM 15/92 mg group. In all cases, cognitive 
disturbances resolved after drug discontinuation. 
In SEQUEL, there was no apparent increase 
in serious suicidal ideation or suicidal behavior 
as assessed during the 108 weeks of observation. 
Depression-related adverse events were 
comparable between groups. Anxiety-related 
adverse events correlated with higher doses. 
Rates of anxiety were found to be 3.1%, 6.5%, 
and 9.5% for placebo, PHN/TPM 7.5/46 mg, and 
PHN/TPM 15/92 mg, respectively. No serious 
anxiety-related events occurred but did lead to 
discontinuation in one PHN/TPM 15/92 mg 
patient and severe symptoms in two additional 
patients in the higher-dose group.
PrEGNANcY OUtcOMEs AND 
POtENtIAL tErAtOGENIcItY
One of the FDA Advisory Panel’s major concerns 
with the approval of PHN/TPM involved the 
teratogenic potential of the drug. Topiramate is 
currently marketed in Pregnancy Category D. In 
some cases, topiramate may be continued during 
pregnancy when the risk of seizures in a woman 
with epilepsy or severe migraines outweighs 
the potential for fetal malformation [22].
In the case of PHN/TPM, the plan is to have 
a contraindication for pregnant women and 
immediately discontinue the drug if a woman 
becomes pregnant during treatment. 
T h e  t e r a t o g e n i c  p o t e n t i a l  o f 
PHN/TPM continues to be investigated. A large, 
observational retrospective study (Fetal Outcome 
Retrospective TopiRamate ExpoSure Study 
[FORTRESS]) is underway to quantify the fetal risk 
associated with topiramate [22]. Other sources of 
data concerning fetal risk with topiramate are 
being evaluated. To date, it appears that during 
the first trimester of pregnancy, topiramate has 
no overall effect on the prevalence of major 
congenital malformations, but may increase 
the prevalence of oral clefts by two- to fivefold. 
Data are currently too limited to conclusively 
determine the true teratogenic potential of 
topiramate. 
Fifteen pregnancies occurred in women 
randomized to PHN/TPM during EQUIP. Of these, 
six resulted in abortion (three spontaneous, three 
elective), and nine resulted in healthy live births 
with no evidence of congenital malformation. 
Two pregnancies occurred in the SEQUEL study, 
one in the placebo group and one in the PHN/
TPM 15/92 mg group. The pregnancy in the 
drug group was carried to term with no evident 
teratogenic effects. 
An additional consideration is that topiramate 
may interfere with the pharmacokinetics of 
hormonal contraceptives. Estrogen and progestin 
levels are reduced by topiramate, particularly 
at doses of >200 mg/day [23]. The dosage of 
topiramate in the combination of PHN/TPM 
15/92 mg was found to reduce the exposure of a 
single dose of ethinyl estradiol 35 µg by 16% and 
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increase the exposure of norethindrone 1 mg by 
22% [25]. The manufacturer states that these 
changes are unlikely to affect contraceptive 
effectiveness, although irregular bleeding may 
occur [25]. Nevertheless, the patient brochure on 
PHN/TPM recommends that oral contraceptives 
be used in combination with barrier methods 
of contraception. It is recommended by the 
manufacturer that women of childbearing 
potential produce a negative pregnancy test at 
baseline and monthly thereafter during therapy. 
This drug will be dispensed only through 
pharmacies certified by the manufacturer. This 
requirement is part of a Risk Evaluation and 
Mitigation Strategy (REMS) to help prevent birth 
defects. To become certified, pharmacies must 
agree to dispense a patient medication guide and 
a brochure with each PHN/TPM prescription that 
specifically warns patients about birth defects 
with PHN/TPM, and pharmacies must agree to 
educate pharmacy personnel accordingly. 
QUALItY OF LIFE
In the CONQUER trial, both health-related 
quality of life and weight-related quality of 
life were assessed; for EQUIP, only weight-
related quality of life was assessed. The Medical 
Outcomes Study Short Form-36 (SF-36) [46] was 
used to assess health-related quality of life, and 
the Impact of Weight on Quality of Life-Lite 
(IWQOL-Lite) was used to assess weight-related 
quality of life [47]. 
Participants receiving PHN/TPM 7.5/46 mg 
and 15/92 mg in both EQUIP and CONQUER 
trials experienced significant improvements 
versus placebo (P < 0.05) on IWQOL-Lite total 
score and all subscales (physical function, self-
esteem, sexual life, public distress, and work). 
Significant differences were observed for 
participants on PHN/TPM 3.75/23 mg only on 
physical function [48]. SF-36 results (CONQUER) 
indicated significant improvements for both 
PHN/TPM groups versus placebo (P < 0.05) on 
physical functioning, physical role, bodily pain, 
general health, vitality, and Physical Component 
Summary. When stratified by weight loss 
(inclusive of all groups), improvements in 
IWQOL-Lite and SF-36 were greater with greater 
weight reductions [48].
cONcLUsION
The authors identified five major points 
regarding PHN/TPM treatment. (1) Weight loss 
exceeds FDA efficacy benchmarks and appears 
to continue or be maintained for at least 2 years 
with continued use of the drug. (2) The most 
common adverse effects include paresthesia, dry 
mouth, and constipation. Among psychiatric 
side effects, anxiety symptoms seem to be 
most common. (3) Laboratory abnormalities 
can include reductions in bicarbonate and in 
some cases hypokalemia. (4) PHN/TPM should 
be avoided in women desiring pregnancy or 
becoming pregnant due to potential teratogenic 
effects associated with topiramate (particularly 
oral cleft defects). (5) Weight loss induced by 
PHN/TPM 7.5/46 mg and 15/92 mg improved 
both weight-specific and physical quality of life 
concerns, but did not improve general mental/
psychosocial concerns.
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